Psychedelics


Optimi Health Acquires Extensive Catalog of Psychedelic and Functional Mushroom Genetics

May 17th, 2022 - Ryan Allway

New strains to provide crucial insights in mental health research across the sector May 17, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has completed the acquisition […]

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

May 12th, 2022 - Ryan Allway

— Review of Phase I ready BMB-101 and upcoming milestones — — Webcast to be held on May 19, 2022, 4:00pm ET —     VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs […]

Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders

May 11th, 2022 - Ryan Allway

The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments   NAPLES, FL, May 11, 2022 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced plans to transfer and spin-off its cannabinoid clinical development pipeline […]

Optimi Health Completes Expansion Of On-Site Analytical Laboratory

May 11th, 2022 - Ryan Allway

Lab’s completion brings Company closer to full commercialization VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed a planned expansion of the on-site analytical laboratory at its Princeton, British Columbia facility. The on-site lab is […]

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors

May 10th, 2022 - Ryan Allway

Preclinical study results demonstrated the combination of SciSparc’s CannAmide™ with Clearmind’s MEAI has the potential to reduce alcohol consumption   TEL AVIV, Israel, May 10, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (“SciSparc”), today announced […]

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

May 10th, 2022 - Ryan Allway

Nets CAD$15,480,780 cash in non-dilutive capital Current cash position of approximately CAD$50 million or approximately CAD $1.30 per share with only 38.4 million shares issued Profit realized on the sale of the non-core asset which was acquired by FSD Pharma in 2017 for CAD$5.5 million FSD continues to enhance shareholder value via the sale of […]

PharmAla Biotech Expands MDMA Distribution with CCrest Labs

May 10th, 2022 - Ryan Allway

PharmAla’s GMP MDMA will now be available for both international and domestic customers through CCrest’s well-developed distribution infrastructure   VANCOUVER, BC, May 10, 2022 /CNW/ – PharmAla Biotech (CSE: MDMA) is excited to announce that it has signed an agreement with CCrest Laboratories Inc. which will allow for its GMP MDMA to be delivered to customers in Canada and […]

Biomind Labs to Argument Which Psychedelic Medicines Will Lead the Industry Into Its Next Phase of Evolution at The National Gallery in London

May 9th, 2022 - Ryan Allway

TORONTO, May 09, 2022–(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or the “Company“) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce that its CEO Alejandro Antalich will […]

Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investments

May 9th, 2022 - Ryan Allway

MIAMI, May 09, 2022 (GLOBE NEWSWIRE) — Mycotopia Therapies Inc. (OTC Pink: TPIA), a biopharma company focused on research, technology, and the development of medical psychedelics, and Ei.Ventures Inc., a technology company empowering mental wellness through psychoactive compounds, nutraceuticals and web 3.0, are pleased to announce several strategic investments to advance the combined company’s business […]

Optimi Health Granted Amendment To Controlled Substances Dealer’s Licence

May 4th, 2022 - Ryan Allway

Request to modify quantities of psilocybin and psilocin receives approval from Health Canada.   VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that a requested Amendment to its Controlled Substances Dealer’s Licence has been granted by Health Canada, enabling it to further expand the capacity to […]

Adastra Holdings Announces 2021 Annual Financial Results and Corporate Update

May 4th, 2022 - Ryan Allway

Generated record gross revenues of $5.6 million in 2021, representing 124% growth YOY Maintained a strong capital position with $28.8 million of assets, and $6.4 million of liabilities LANGLEY, BC, May 4, 2022 /CNW/ – Adastra Holdings Ltd. (CSE: XTRX) (FRA: D2EP) (“Adastra” or the “Company”) is pleased to announce that it has filed its consolidated financial statements and related management discussion and […]

Novamind Announces Virtual Group Health Coaching

May 2nd, 2022 - Ryan Allway

Collaboration with HealCommunity offers remote access to reimbursable group therapy option   TORONTO, ON / May 2, 2022 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce its collaboration with virtual health coaching experts, HealCommunity, to provide remote […]

TRYP Therapeutics Doses First Patient In Phase II Psilocybin-Assisted Therapy Clinical Trial

April 27th, 2022 - Ryan Allway

Phase II trial to determine efficacy of psilocybin in combination with psychotherapy for potential treatment of Binge Eating Disorder San Diego, California — (April 27, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that the […]

Doseology Accelerates Rollout of Medicinal Mushroom Products with National Distribution

April 22nd, 2022 - Ryan Allway

VERNON, BC, April 22, 2022 /CNW/ — Doseology Sciences Inc.. (CSE: MOOD) (FSE: VU7) (“Doseology” or the “Company”), a life sciences company focused on mental health and wellness, is excited to announce it has signed a Distribution Agreement with Peak Performance Products Inc. (“Peak”) for the distribution of the Company’s medicinal mushroom products across Canada. Doseology Sciences Inc. Logo […]

Company Leverages Household Brand Status in Effort to be World’s Largest Chain of Psychedelic Mental Health Clinics

April 18th, 2022 - Ryan Allway

LOS ANGELES, April 18, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it has taken the next step in the execution of its ketamine clinic roll-up strategy – a move the Company says is motivated by an intention to become the world’s largest chain of psychedelic […]

Psychedelics Company Silo Wellness Announces Financing Commitment of CAD$5,950,000 in Convertible Debentures

April 14th, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – April 14, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, is pleased to announce that Alpha Blue Ocean (“ABO“), is supporting the Company’s growth with this new CAD$5,950,000 financing arrangement. The Company entered into a subscription agreement (the […]

PharmAla Biotech to supply Mind Medicine Australia with GMP MDMA for Clinical Trial

April 11th, 2022 - Ryan Allway

PharmAla’s GMP MDMA will accelerate trial work funded by Australia’s premier Psychedelics charity PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for Mind Medicine Australia. Mind Medicine Australia’s order will be available for delivery later this year, for use in an ethics approved healthy persons trial and will be subject […]

PharmaDrug Advances DMT-Analogue Program for Glaucoma with Production of Medical Device Designed to Provide Sustained Control of Elevated Intraocular Pressure

April 7th, 2022 - Ryan Allway

Prototype medical device engineered to deliver sustained, sub-psychedelic quantities of candidate DMT-analogues In vitro, time dependent drug elution profile evaluated for three candidate molecules Biocompatibility of drug-loaded medical device demonstrates cell-based safety at doses anticipated to be within therapeutic range Current results provide Company with refined focus for two candidate molecules   Toronto, Ontario–(Newsfile Corp. […]

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

March 31st, 2022 - Ryan Allway

TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure ketamine’s psychedelic effects on cerebral cortex hemodynamics.   “The commencement of the Kernel feasibility study marks […]

Revitalist Increases Clinic Count to 10 with the Acquisition of a Virginia Ketamine Clinic

March 29th, 2022 - Ryan Allway

VANCOUVER, British Columbia, March 29, 2022–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company“) (CSE: CALM) (CSNX: CALM.CN) (OTC: RVLWF) is pleased to announce that has it has entered into a definitive agreement (“Merger Agreement“) to acquire Alchemy Wellness (“Alchemy“) a ketamine clinic (“Acquisition“) located in Richmond, Virginia (“Virginia Clinic“). The Acquisition, which was previously […]

Psychedelic Pharmaceutical Startup Ninnion Announces Formation of World Renowned Scientific Advisory Board

March 28th, 2022 - Ryan Allway

Board members include industry pioneers Dr. Rick Strassman and Dr. Charles B Nemeroff   AUSTIN, TX –News Direct– Ninnion   Ninnion, a clinical-stage pharmaceutical company focused on developing next-generation psychedelic therapeutics today announced the formation of its Scientific Advisory Board (SAB). The board is composed of key opinion leaders in pharmaceutical development and psychedelics research, […]

Adastra Announces Completed Submission of Controlled Substances Dealer’s License Application

March 25th, 2022 - Ryan Allway

LANGLEY, BC, March 25, 2022 /CNW/ – Adastra Holdings Ltd. (CSE: XTRX) (FRA: D2EP) (“Adastra” or the “Company”) a Health Canada Licensed cannabis company focused on processing, sales, organoleptic testing and analytical testing, is pleased to announce it completed the submission of its application for a Controlled Drugs and Substances Dealer’s License (“Dealer’s License”) on March 23, 2022. […]

Real Brands Announces Entry to Medical Psychedelics Market, Partners with Marcu & Arora for Licensure, R&D

March 24th, 2022 - Ryan Allway

Real Brands applying for DEA psychedelics licensure Psychedelics drugs market size is projected to reach $10.75 billion by 2027 Real Brands planning to leverage new clinical research to produce and deliver safe, nature-based psychedelics product formulations that will effectively treat mental health conditions   North Providence, RI, March 24, 2022 (GLOBE NEWSWIRE) — Real Brands Inc. (OTCQB: […]

PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease

March 23rd, 2022 - Ryan Allway

100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well tolerated with no serious adverse events reported Study results are adequate to give an effect size in powering a Phase 3 clinical study PharmaTher planning a Phase 3 clinical study to allow for FDA […]

Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida

March 23rd, 2022 - Ryan Allway

Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders San Diego, California–(March 23, 2022) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the first […]

Revitalist Launches UNIT Initiative Working With Veteran and First Responder Non-Profits Across the United States Creating Nationwide Guidelines

March 22nd, 2022 - Ryan Allway

VANCOUVER, British Columbia, March 22, 2022–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) is pleased to announce the launch of the UNIT initiative, a nationwide project focused on providing veterans and first responders access to mental health solutions through qualified, and compassionate medical providers.   One of […]

Virtual Psychedelic Therapy Company TripSitter.Clinic is Joined by Reconcious Medical

March 22nd, 2022 - Ryan Allway

Four (4) psychedelics industry professionals will join the TripSitter.Clinic team, including Dr. Mark Braunstein, world renowned ketamine and cannabis psychiatrist.   TripSitter.Clinic’s current patient services will be updated & new offerings added   TripSitter.Clinic’s technology platform will be enhanced with new native iOS and Android apps to provide improved patient & practitioner experiences   TORONTO, March 22, […]

Optimi Health Begins Cultivation Of Natural Psilocybin For Use In Clinical Trials

March 18th, 2022 - Ryan Allway

VANCOUVER, British Columbia, March 18, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British Columbia facility.   “These mushrooms are an important milestone in Optimi’s commitment to establishing […]

Irwin Naturals Completes Acquisition of Midwest Ketafusion

March 17th, 2022 - Ryan Allway

Transaction Marks Start to Execution of Rollup Strategy LOS ANGELES, March 17, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today that further to its press release dated February 9, 2022, the Company has now completed the acquisition of its first ketamine clinic, Midwest Ketafusion (“Ketafusion”). In […]

Nova Mentis Announces Closing of Non-Brokered Financing

March 15th, 2022 - Ryan Allway

VANCOUVER, BC, March 15, 2022 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it has completed a non-brokered private placement financing for total gross proceeds of $1,483,500 (the “Placement”).   The Company has issued 29,670,000 units […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading